PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1427443-0 1992 Ultrastructural, immunologic and clinical follow-up of five patients with HCL treated with interferon (IFN) for more than three years. Hydrochloric Acid 74-77 interferon alpha 1 Homo sapiens 91-107 1427443-1 1992 BACKGROUND: Treatment results in HCl have been improved by the use of alpha-IFN, which is now the standard first-line therapy for this disease, but the mechanism of IFN action is still unclear. Hydrochloric Acid 33-36 interferon alpha 1 Homo sapiens 76-79 1427443-1 1992 BACKGROUND: Treatment results in HCl have been improved by the use of alpha-IFN, which is now the standard first-line therapy for this disease, but the mechanism of IFN action is still unclear. Hydrochloric Acid 33-36 interferon alpha 1 Homo sapiens 165-168 1427443-4 1992 METHODS: We assessed the phenotype membrane and ultrastructural changes induced in HCs by long-term alpha-IFN treatment in five pts with HCL; membrane-bound Il 2-R on PHA-stimulated PBL, the release of IL 2-R by PHA-stimulated PBL and the serum levels of s-IL 2-R were also determined in one pt. Hydrochloric Acid 137-140 interferon alpha 1 Homo sapiens 106-109 1427443-5 1992 RESULTS: The surface immunological phenotype, mainly the HCL-related surface antigen CD25, changed after IFN treatment, dropping from abnormally high to normal values. Hydrochloric Acid 57-60 interleukin 2 receptor subunit alpha Homo sapiens 85-89 1427443-5 1992 RESULTS: The surface immunological phenotype, mainly the HCL-related surface antigen CD25, changed after IFN treatment, dropping from abnormally high to normal values. Hydrochloric Acid 57-60 interferon alpha 1 Homo sapiens 105-108